Duchenne Muscular Dystrophy Drugs Market Size and Report 2023-2028
IMARC Group, a leading market research company, has recently releases report titled “Duchenne Muscular Dystrophy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global Duchenne muscular dystrophy drugs market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
What is Duchenne Muscular Dystrophy Drugs
Duchenne muscular dystrophy (DMD) drugs are used to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that mainly affects the male population and rarely females as well. The symptoms of this disorder include difficulty in walking, standing, sitting, etc., which can result in progressive weakness and loss, also called atrophy, in the skeletal and heart muscles. DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. The market for Duchenne muscular dystrophy drugs attained a global size of US$ 2.04 Billion in 2022. It is projected to expand significantly, reaching US$ 4.00 Billion by the year 2028. This growth reflects a compound annual growth rate (CAGR) of 11.41% between the years 2023 and 2028.
Types of Duchenne Muscular Dystrophy Drugs
Duchenne muscular dystrophy (DMD) drugs encompass different types of treatments and therapies for individuals with DMD:
-
Steroids: Commonly prescribed corticosteroids like prednisone and deflazacort are used to alleviate inflammation and slow down muscle degeneration. These drugs aim to enhance muscle strength and function.
-
Gene-based therapies: Emerging therapies focus on addressing the genetic cause of DMD. This includes innovative approaches like gene replacement therapies, such as exon skipping and gene editing, which aim to restore the production of the dystrophin protein that is lacking in individuals with DMD.
-
Supportive therapies: These therapies are designed to manage the symptoms and complications associated with DMD. They encompass various approaches like respiratory support, physical therapy, occupational therapy, and cardiac management.
-
Emerging therapies: Ongoing research and development efforts are aimed at identifying new treatments for DMD. This includes investigational drugs and therapies that target specific pathways involved in the progression of the disease.
What are the Causes of Duchenne Muscular Dystrophy Drugs
Duchenne muscular dystrophy (DMD) is primarily caused by genetic mutations that affect the production of a protein called dystrophin. The gene responsible for producing dystrophin is located on the X chromosome. In most cases, DMD is inherited in an X-linked recessive pattern, which means it predominantly affects males.
The most common cause of DMD is a mutation in the DMD gene, leading to a deficiency or absence of dystrophin. This protein plays a crucial role in maintaining the structural integrity of muscle cells. Without sufficient dystrophin, muscle fibers become fragile and susceptible to damage, resulting in the progressive muscle weakness and degeneration characteristic of DMD.
DMD mutations can occur spontaneously during the development of an embryo or be inherited from a carrier mother. Females who carry a single copy of the mutated gene are typically unaffected or may exhibit milder symptoms due to the presence of a second normal copy of the gene on their other X chromosome. However, they have a 50% chance of passing the mutated gene to their children.
What Are the Growth Prospects and Trends in The Duchenne Muscular Dystrophy Drugs Industry?
The rising number of new product approvals and launches by leading manufacturers is among the key factors stimulating the Duchenne muscular dystrophy drugs market. Moreover, the increasing incidences of DMD among individuals are acting as significant growth-inducing factors. Besides this, the inflating clinical trials and the wide presence of a strong pipeline of medications are positively influencing the global market. Furthermore, the introduction of mutation-specific therapies, owing to the continuous innovations in diagnostics, is propelling the market growth. Apart from this, extensive R&D activities focusing on accurate diagnosis and treatment of Duchenne muscular dystrophy for underserved categories, such as infants, females, and non-ambulant patients, are further catalyzing the global market. Additionally, the launch of favorable initiatives by government bodies to provide reimbursement policies and promote target-specific treatments is also augmenting the market growth. In line with this, the expanding medical infrastructures, the emerging trend of product premiumization, and the growing disposable income levels of consumers are anticipated to fuel the Duchenne muscular dystrophy drugs market over the forecasted period.
Top Key Companies Involved in Duchenne Muscular Dystrophy Drugs Industry
-
FibroGen Inc.
-
Italfarmaco S.p.A.
-
NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
-
PTC Therapeutics Inc.
-
Santhera Pharmaceuticals
-
Sarepta Therapeutics Inc.
Final Words
In conclusion, Duchenne muscular dystrophy (DMD) is a genetic disorder primarily caused by mutations in the DMD gene, leading to a deficiency or absence of the dystrophin protein. This results in progressive muscle weakness and degeneration. DMD is typically inherited in an X-linked recessive pattern, predominantly affecting males. While the exact cause may vary between individuals, the underlying genetic mutations disrupt the structural integrity of muscle cells, making them more vulnerable to damage.
